Microart, Inc. Announces Stem Cell Agency Agreement

HONG KONG, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Microart, Inc. ("MCRT" or the "Company") (OTC:MCRT), a Nevada Corporation, is pleased to announce that it has signed an agency agreement to market stem cell treatments in Germany to its clients in Asia.

The Company has signed an agency agreement with Gali Klinik Limited "Gali", based in Neustadt an der Weinstrabe, Germany.

Tsap Wai Ping, CEO stated, "our agreement with Gali is a significant step forward in our business plan and developing our stem cell therapy business with a global leader in the field."

Gali Klinik is a fully licensed Hospital in Germany, fully compliant with government regulations to provide professional Fresh Cell Therapy to patients. Gali Klinik, is committed to promoting life-long physical well-being and youthful exuberance to its patients. Gali believes that youth is not about a person's appearance or the actual age. It is associated with one's energy level, vitality, and physical wellbeing. This can be achieved through the provision of the safest treatment with the highest medical standards accompanied by our excellent services, which are tailor-made for each patient. Website: http://galiklinik.com/index.html

Microart Inc. is a global leader of innovative stem cell solutions, the therapeutic applications of Adult stem cells and the development and commercialization of cell-based anti-aging research and cosmetic products. Microart Inc. is also developing proprietary technology seeking to revolutionize the treatment of diabetes.

CONTACT: Tsap Wai Ping, President & CEO Microart, Inc. 2611 Office Tower, Langham Place, 8 Argyle Street, Kowloon, Hong Kong. Tel +852-3111-7718 info@mcrtus.com www.mcrtus.comSource:Microart, Inc.